M. van Glabbeke - Concepedia

Author

M. van Glabbeke

European Organisation for Research and Treatment of Cancer

Also Known As

A. van Oosterom, M V Glabbeke, M Van Glabbeke, M van Glabbeke, M. V. Glabbeke, M. Van Glabbeke, M. van Glabbeke, M.V. Glabbeke, M.v. Glabbeke, M.van Glabbeke

247

Publications

45.8K

Citations

H-Index

Concepts

All Affiliations

European Organisation for Research and Treatment of Cancer Institut Gustave Roussy Centre Léon Bérard The Netherlands Cancer Institute Royal Marsden Hospital

About

M. van Glabbeke is an author at European Organisation for Research and Treatment of Cancer specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	50	98	30.5K
2	Health Sciences	25	34	20.6K
3	Biostatistics	3	3	15.7K
4	Natural Sciences	1	1	14
5	Biochemistry	1	1	14

M. van Glabbeke

144

Publications

41.9K

Citations

H-Index

Page 1

	Year	Citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer Jacques Bernier, C. Domenge, Mahmut Özsahin, New England Journal of Medicine	2004	3.1K
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) Jacques Bernier, Jay S. Cooper, Thomas F. Pajak, Head & Neck Surgical OncologyExtracapsular ExtensionSurgeryOnly Risk FactorsRadiation Medicine	2005	1.7K
Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. Harry Bartelink, F. Roelofsen, F. Eschwège, Journal of Clinical Oncology	1997	1.3K
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Allan T. van Oosterom, Ian Judson, Jaap Verweij, The Lancet OncologyGastrointestinal OncologyMedicinePathologyCancer Treatment	2001	1.3K
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Maria Dêbiec‐Rychter, Raf Sciot, Axel Le Cesne, European Journal of Cancer OncologyGastrointestinal OncologyMedicineKit MutationsDose Selection	2006	893
Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas Isabelle Ray‐Coquard, Claire Cropet, M. van Glabbeke, Cancer Research	2009	780
A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844 Abul B.M.F. Karim, B. Maat, Reidulv Hatlevoll, International Journal of Radiation OncologyBiologyPhysics Neuro-oncologyRadiation MedicineRadiation TherapyMedicineNeurology	1996	696
Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy Jean-Claude Horiot, R. Le Fur, T. Nguyen, Radiotherapy and Oncology Neuro-oncologySurgical OncologyConventional FractionationRadiation TherapyMedicine	1992	682
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043) Stefan Sleijfer, Isabelle Ray‐Coquard, Zsuzsa Pápai, Journal of Clinical Oncology OncologyAngiogenesisBone Sarcoma GroupSoft Tissue SarcomaPharmacology	2009	674

Page 1